BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 186 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2019. The put-call ratio across all filers is 0.14 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $62,131,000 | -3.7% | 524,000 | +12.0% | 1.20% | +13.8% |
| Q4 2021 | $64,495,000 | +23.5% | 468,000 | +24.5% | 1.06% | +19.2% |
| Q3 2021 | $52,230,000 | +7.6% | 376,000 | -24.8% | 0.88% | +1.8% |
| Q2 2021 | $48,540,000 | -29.0% | 500,000 | -50.0% | 0.87% | -44.6% |
| Q1 2021 | $68,350,000 | +39.4% | 1,000,000 | +74.8% | 1.57% | -5.9% |
| Q4 2020 | $49,026,000 | -16.2% | 572,000 | -36.4% | 1.67% | -21.4% |
| Q3 2020 | $58,509,000 | +60.1% | 900,000 | +80.0% | 2.12% | +32.4% |
| Q2 2020 | $36,555,000 | +1.7% | 500,000 | -52.7% | 1.60% | -27.9% |
| Q1 2020 | $35,936,000 | +7.9% | 1,056,000 | +72.5% | 2.22% | +15.6% |
| Q4 2019 | $33,317,000 | +38.2% | 612,000 | +5.9% | 1.92% | +20.3% |
| Q3 2019 | $24,114,000 | +244.2% | 578,000 | +261.2% | 1.60% | +261.5% |
| Q2 2019 | $7,006,000 | – | 160,000 | – | 0.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
| Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
| ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
| DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
| Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
| Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |